DAFTAR PUSTAKA

[1] WHO, “Hipertensi,” World Health Organization.

[2] WHO, “Persentase Kematian Akibat Hipertensi,” Healthline.

[3] Kemenkes RI, “Prevalensi Hipertensi Indonesia,” Databoks.

[4] Kemenkes RI, “Kematian Akibat Hipertensi,” Kantor Berita Kemanusiaan.

[5] SKI, “Prevalensi Hipertensi Jawa Tengah,” Suaramerdeka.com. [Online]. Available: 28 April 2026

[6] E. A. W. H. Y. H. B. M. S. F. F. D. R. Sugiyartono, “Analysis of Factors Affecting Potential Drug Interactions in Outpatient Hypertension Patients at Dr . Iskak Tulungagung Hospital,” *J. Farm. Galen.*, vol. 12, no. 1, pp. 37–47, 2026, doi: 10.22487/j24428744.2026.v12.i1.17803.

[7] Y. G. E. Deswati and K. Armal, “Analisis Potensi Interaksi Obat Antihipertensi pada Paien Geriatri di Instalasi Rawat Jalan RSUD Dr. Achmad Mochtar Bukittinggi Tahun 2023,” *J. Kesehat.*, vol. 2, no. 10, pp. 306–312, 2024.

[8] B. S. L. A. I. Yudyawati, “Hipertensi Masa Kini dalam Perspektif Kesehatan Masyarakat,” 2020.

[9] ESH, “Pedoman Hipertensi Arteri,” European Society of Hypertension.

[10] S. Nurvita, “Literature Riview Gambaran Hipertensi di Indonesia,” *J. Rekam Medis dan Manaj. Inf. Kesehat.*, vol. 1, no. 2, p. 5, 2025, [Online]. Available: https://unkartur.ac.id/journal/index.php/jurmik/article/view/34/79

[11] N. D. K. D. D. Ariwibowo, “Gambaran Komplikasi Hipertensi di RSUD Cengkareng Tahun 2021-2022,” *J. Sehat Indones.*, vol. 7, no. 1, pp. 370–381, 2025, [Online]. Available: najwa.405210218@stu.untar.ac.id

[12] T. R. H. N. Basya, “Analisis Sistematis Hubungan Hipertensi dengan Risiko Gagal Ginjal Kronik,” *J. Ilm. Penelit. Mhs.*, vol. 3, no. 1, pp. 618–624, 2025.

[13] L. S. A. W. C. A. M. S. E. T. E. B. M. T. S. S. R. Q. Maalikie, “Edukasi Pencegahan Hipertensi Sebagai Upaya Meningkatkan Pengetahuan,” *J. Pengabdi. Masy. Indones.*, vol. 4, no. 5, pp. 817–822, 2024.

[14] T. R. A. T. S. M. T. R. Fithri, “Evaluasi Penggunaan Obat Antihipertensi pada Pasien Rawat Jalan di RSUD X Kabupaten Bekasi,” *J. Farm. Malahayati*, vol. 8, no. 2, pp. 296–308, 2025.

[15] J. L. Jameson, A. S. Fauci, D. L. Kasper, S. L. Hauser, and J. Loscalzo, *Harrison’s Principles of Internal Medicine*, 20th ed. New York: McGraw-Hill Education, 2018.

[16] T. M. M. Notes, *Basic Pharmacology & Drugs Notes*, 4th ed. Makasar: MMN Publishing, 2025.

[17] R. L. Maher, J. Hanlon, and E. R. Hajjar, “Clinical consequences of polypharmacy in elderly,” *Expert Opin. Drug Saf.*, vol. 13, no. 1, pp. 57–65, Jan. 2021, doi: 10.1517/14740338.2013.827660.

[18] N. Masnoon, S. Shakib, L. Kalisch-Ellett, and G. E. Caughey, “What is polypharmacy? A systematic review of definitions,” *BMC Geriatr.*, vol. 17, no. 1, Oct. 2017, doi: 10.1186/s12877-017-0621-2.

[19] A. Rankin *et al.*, “Interventions to improve the appropriate use of polypharmacy for older people,” *Cochrane Database Syst. Rev.*, vol. 2021,

no. 9, Sep. 2021, doi: 10.1002/14651858.CD008165.pub4.
[20] A. Nicholson and B. Stone, “Evidence to the Royal Commission on the National Health Service,” *Br. J. Clin. Pharmacol.*, vol. 5, no. 6, pp. 475–480, 2021, doi: 10.1111/j.1365-2125.1978.tb01659.x.
[21] A. Arlayati and I. Ikhwan, “Analisis Faktor Komorbiditas sebagai Prediktor Mortalitas Sepsis di Unit Perawatan Intensif Ardi,” *J. Anastesi Peroperatif*, vol. 8, no. 2, pp. 187–199, 2025, doi: 10.24036/perspektif.v8i2.1083.
[22] D. S. Monoarfa *et al.*, “Analisis Hubungan Komorbid Hipertensi dengan Kualitas Hidup Pasien Gagal Ginjal Kronik yang Menjalani Hemodialisis Analysis of the Relationship Between Comorbid Hypertension and the Quality of Life of Patients with Chronic Renal Failure Undergoing Hemodia,” *J. Farm. Indones.*, vol. 22, no. 02, 2025.
[23] N. K. Chaurasia, M. Mothashin, and M. G. Hossain, “Prevalence and determinants of comorbidities among patients with type 2 diabetes mellitus in Nepal,” *BMC Endocr. Disord.*, vol. 25, no. 1, p. 247, Nov. 2025, doi: 10.1186/s12902-025-02068-y.
[24] F. Apriliany, Z. Ikawati, and I. D. P. Pramantara, “Pengaruh Komorbid dan Jenis Terapi terhadap Outcome Kolesterol Total Pasien Dislipidemia,” *J. Manag. Pharm. Pract.*, vol. 11, no. 3, p. 153, Sep. 2021, doi: 10.22146/jmpf.64328.
[25] Adinugraha Amarullah, Rifdah Nuur Ronaa Puteri, I. C. S. Klau, Farida Anwari, Bella Fevi Aristia, and Hamidah, “Analisis Potensi Interaksi Obat pada Pasien Layanan Apotek,” *J. Farm. Ma Chung*, vol. 3, no. 1, pp. 30–33, 2025, doi: 10.33479/jfmc.v3i1.59.
[26] M. Kania and S. Adiana, “Analisis Potensi Interaksi Obat Pada Pasien Rawat Jalan Eksekutif Poliklinik Penyakit Dalam Di Rumah Sakit X Periode Januari-Maret 2023,” *Indones. J. Heal. Sci.*, vol. 4, no. 4, pp. 292–297, 2024, doi: 10.54957/ijhs.v4i4.932.
[27] Annisa Maulida Azzahra and Yasmiwar Susilawati, “Kajian Interaksi Obat pada Resep Polifarmasi Dokter Spesialis Dalam Periode April 2024 di Salah Satu Apotek di Kota Bandung,” *J. Ilmu Kesehat. dan Gizi*, vol. 2, no. 3, pp. 185–191, 2024, doi: 10.55606/jig.v2i3.3123.
[28] S. Y. Oktavia, L. D. Ardi, and D. Almasdy, “Kajian Potensi Interaksi Obat pada Pasien Rawat Jalan dengan Polifarmasi di RSUD HAMBA Batang Hari Tahun 2020,” *J. Penelit. dan Kaji. Ilm.*, vol. 17, no. 1, pp. 71–82, 2020, [Online]. Available: www.drugs.com
[29] Z. Farah, D. Sutrisno, and A. D. Mitra, “Analisis Interaksi Obat Secara Farmakokinetik dan Farmakodinamik Terhadap Pasien Nefropati Diabetik di Rumah Sakit X Kota Jambi Tahun 2022,” *J. Ilm. Univ. Batanghari Jambi*, vol. 24, no. 1, p. 320, 2024, doi: 10.33087/jiubj.v24i1.4688.
[30] H. Hasnita, F. M. Afendi, and A. Fitrianto, “Perbandingan Beberapa Metode Klasifikasi Dalam Memprediksi Interaksi Farmakodinamik,” *Indones. J. Stat. Its Appl.*, vol. 4, no. 1, pp. 11–21, 2020, doi: 10.29244/ijsa.v4i1.328.
[31] P. M. A. E. Tirta, P. P. Empuadji, and P. Y. B. Setiawan, “Retrospective Study of Potential Interactions of Hypertension Drug Interactions on Patient Potential At Private X Hospital in Denpasar,” *Ris. Kesehat. Nas.*, vol. 7, no.

2, pp. 1–6, 2023.
[32] L. Efriani, T. A. Putra, and H. N. Fauzia, “Analisis Interaksi Obat Antipsikotik pada Pasien Bipolar di Rumah Sakit Jiwa Provinsi Jawa Barat Periode Januari-Desember 2023,” *J. Sehat Indones.*, vol. 7, no. 01, pp. 204–216, 2024, doi: 10.59141/jsi.v7i01.178.
[33] N. Sinata, I. D. Pratiwi, and R. Rusnedy, “Potensi Interaksi Obat Pada Pasien Infeksi Saluran Kemih Sistitis Tahun 2021 Di RSUD Arifin Achmad Provinsi Riau,” *J. Mandala Pharmacon Indones.*, vol. 9, no. 2, pp. 524–531, 2023, doi: 10.35311/jmpi.v9i2.430.
[34] Salma Tri Octaviany and Tina Rostinawati, “Identifikasi Interaksi Obat pada Resep dengan Diagnosa Gangguan Sistem Endokrin Periode Bulan Juli 2024 di Rumah Sakit X Kota Bandung,” *OBAT J. Ris. Ilmu Farm. dan Kesehat.*, vol. 3, no. 1, pp. 232–240, 2025, doi: 10.61132/obat.v3i1.1026.
[35] S. P. Tw, D. A. Yani, A. A. Zuniarto, R. I. Muwahid, and S. Pandanwangi, “Analisis Potensi Interaksi Obat pada Resep Spesialis Saraf di RSUD X Kabupaten Majalengka Analysis of Potential Drug Interactions in Neurology Specialist Prescriptions at RSUD X Majalengka Regency,” *Pharm. J. Farm. Indones.*, vol. 22, no. 1, pp. 32–36, 2025, [Online]. Available: https://jurnalnasional.ump.ac.id/index.php/PHARMACY
[36] M. Jayanti, Utami Sasmita Lestari, and Sri Sudewi, “Kajian Interaksi Obat Potensial di Ruang Rawat Jantung Salah Satu Rumah Sakit di Manado: Studi Retrospektif,” *Pharmacon*, vol. 14, no. 1, pp. 873–883, 2025, doi: 10.35799/pha.14.2025.61840.
[37] N. Audina, J. F. Suparningtyas, and H. Herman, “Kajian Potensi Interaksi Obat pada Pasien Infeksi Saluran Kemih di RSUD Inche Abdoel Moeis Samarinda Periode Tahun 2021,” *J. Sains dan Kesehat.*, vol. 5, no. SE-1, pp. 27–32, 2023, doi: 10.25026/jsk.v5ise-1.2051.
[38] N. Wibisono, D. N. Wulandari, M. Sengaji, H. Fadilah, and N. Romadhoni, “Analisis Potensi Interaksi Obat pada Resep Penyakit Degeneratif di Klinik X, Kabupaten Malang,” *Sci. J.*, vol. 4, no. 6, pp. 459–466, 2025, doi: 10.56260/sciena.v4i6.291.
[39] D. Kurniawati, Tri Cahyani Widiastuti, and Khusnul Khuluq, “Potensi Interaksi Obat Pada Pasien Hipertensi Dengan Penyakit Penyerta Di Rsud Prembun,” *J. Farm. Lampung*, vol. 13, no. 2, 2024, doi: 10.37090/jfl.v13i2.1762.
[40] H. Afifah, E. M. A. Rachmawati, and D. Holidah, “Kajian Interaksi Obat Pada Pasien Diabetets Melitus Tipe 2 dengan Komplikasi Hipertensi di RS X Kabupaten Jember,” *J. Farm.*, vol. 6, no. 2, 2024.
[41] Jelly Permatasari, Aisa Dinda Mitra, and Miftahul Ilmi, “Analisis interaksi obat antihipertensi pada resepPolifarmasi pasien hipertensi rawat jalan di rumahSakit x di kabupaten batang hari periode januari -Maret tahun 2023,” *J. Kesehat. Tambusai*, vol. 5, no. 1, pp. 2777–0524, 2024.
[42] M. F. N. Tanty, H. N. Tanty, and A. E. Rosaqh, “Polifarmasi dan potensi interaksi obat: Studi pada pasien geriatri hipertensi rawat inap di RS Islam Jakarta Pondok Kopi (Maret 2024–Februari 2025),” *J. Farm. IKIFA*, vol. 4, no. 3, pp. 103–115, 2025, [Online]. Available:

https://epik.ikifa.ac.id/jfi/article/view/376
[43] S. Ishak *et al.*, *Motodologi Penelitian Kesehatan*, 1st ed. Bandung: Media Sains Indonesia, 2020.
[44] Sugiyono, *Metode Penelitian Kuantitatif, Kualitatif dan R &Metode Penelitian Kuantitatif, Kualitatif Dan R & D*, 3rd ed. Bandung, 2019.
[45] S. H. Sahir, *Metodologi Penelitian*, 1st ed. Yogyakarta: Penerbit KBM Indonesia, 2022.
[46] E. P. Ratri, D. Wahyono, and G. F. Galistiani, "Polifarmasi dan Interaksi Obat pada Pasien Gagal Ginjal Kronis yang Menjalani Hemodialisa," *J. Farm. Indones.*, vol. 22, no. 01, pp. 55–59, 2025.
[47] C. Mélot, "Multivariate analysis: An overview," *Rev. Mal. Respir.*, vol. 22, no. 4, pp. 687–690, 2005, doi: 10.1016/s0761-8425(05)85622-0.
[48] A. I. Safitri and U. A. Nurhayati, "Interaksi Jenis Kelamin, Indeks Massa Tubuh, Perilaku Menetap (Sedentary Behavior) Terhadap Hipertensi Pada Lansia, Serta Dampaknya Pada Kualitas Hidup," *Borneo Nurs. J.*, vol. 8, no. 2, pp. 1179–1188, 2026, doi: 10.61878/bnj.v8i2.659.
[49] "Analisis Efektivitas Biaya Kombinasi Pengobatan Hipertensi Amlodipin-Candesartan dan Bisoprolol-Candesartan pada Pasien Rawat Jalan di RSUD Soeselo Slawi Kabupaten Tegal Tahun 2025," *J. Univ. Perad.*, 2025.
[50] E. K. Simangunsong and B. Hutabarat, "Characteristics of Hypertensive Patients Engaged in 'Non-Communicable Disease Control' Activities at Public Health Centers in Samosir Regency, North Sumatera, Indonesia in April 2024," *J. Hypertens.*, vol. 43, no. Suppl 2, p. e3, May 2025, doi: 10.1097/01.hjh.0001118520.29950.df.
[51] D. Cseh *et al.*, "Phenotypes of Hypertension: Impact of Age and Sex on Hemodynamic Mechanisms," *J. Am. Heart Assoc.*, vol. 14, no. 17, Sep. 2025, doi: 10.1161/JAHA.125.042096.
[52] P. H. O. Ramos *et al.*, "Hypertension in the elderly: Determining factors for non-adherence to drug therapy, potentiated by the Covid-19 pandemic," in *GLOBAL HEALTH TRENDS AND PERSPECTIVES IN HEALTH SCIENCES*, Seven Editora, 2023. doi: 10.56238/globalhealthprespesc-064.
[53] Y. Li *et al.*, "Multimorbidity in elderly patients with or without T2DM: A real-world cross-sectional analysis based on primary care and hospitalisation data," *J. Glob. Health*, vol. 14, p. 04263, Dec. 2024, doi: 10.7189/jogh.14.04263.
[54] Y. Li, X. Su, Z. Ge, S. Li, and J. Li, "Status fungsi kognitif dan korelasinya dengan pengendalian tekanan darah pada pasien hipertensi di Tiongkok," *Zhonghua Xin Xue Guan Bing Za Zhi*, vol. 52, no. 12, pp. 1397–1404, 2024, [Online]. Available: https://pubmed.ncbi.nlm.nih.gov/39681442/
[55] N. Z. Salsabila, C. Y. Pardilawati, D. A. Ramdini, and . Oktafany, "Potential Drug-Drug Interactions and Associated Factors on Ambulatory Patients with Hypertension of a Secondary Care Hospital in Bandar Lampung," in *Proceedings of the 1st International Conference on Medical Science and Health*, SCITEPRESS - Science and Technology Publications, 2023, pp. 21–24. doi: 10.5220/0013101600003873.
[56] Estrin Amalia Fadilah, Suwendar, and Bambang Tri Laksono, "Kajian

Interaksi Obat Pasien Hipertensi Gagal Ginjal Kronis di RS X," *Bandung Conf. Ser. Pharm.*, vol. 5, no. 2, 2025, doi: 10.29313/bcsp.v5i2.19822.

[57] L. E. Lilia Edith, M. A. Osorio García, D. Delgadillo Guzmán, I. Castillo Maldonado, and C. E. Corvera Aispuro, "Pharmacological interactions between antihypertensive regimens and drugs prescribed in the emergency department," *Ann. Pharm. Françaises*, vol. 83, no. 6, pp. 1130–1138, Nov. 2025, doi: 10.1016/j.pharma.2025.05.006.

[58] E. Rogero-Blanco *et al.*, "Drug interactions detected by a computer-assisted prescription system in primary care patients in Spain: MULTIPAP study," *Eur. J. Gen. Pract.*, vol. 27, no. 1, pp. 90–96, Jan. 2021, doi: 10.1080/13814788.2021.1917543.

[59] J. Shareef, S. B. Sridhar, S. A. Hamouda, A. Ali, and A. C. Thomas, "Prescribing Practices, Polypharmacy, and Drug Interaction Risks in Anticoagulant Therapy: Insights from a Secondary Care Hospital," *J. Clin. Med.*, vol. 15, no. 2, p. 800, Jan. 2026, doi: 10.3390/jcm15020800.